Baby Boomers looking to put new money to work may wish to check out the broader basket of dividend stocks while interest ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The company's strong cash flow supports continued dividend growth and business ...

For fiscal 2024, analysts expect PFE to report an EPS of $2.66, up 44.6% from $1.84 in fiscal 2023 . Shares of PFE have ...

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In the latest market close, Pfizer (PFE) reached $29.08, with a -0.27% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.77%. Meanwhile, the Dow ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.03% of ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

Pfizer is facing a messy showdown this week after an outside bid to revive the company’s post-Covid share plunge took an ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price ...

Marcum Wealth LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 5.2% in the 3rd quarter, ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...